Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective

BMC Dermatology

Volumn 10, Issue , 2010, Pages

  Blank, Patricia R ^a   Blank, Armin A ^b   Szucs, Thomas D ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Dermatology FMH   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALITRETINOIN; CLOBETASOL PROPIONATE; ETHINYLESTRADIOL; LEVONORGESTREL; METHOXSALEN; MOMETASONE FUROATE; PLACEBO; PREDNISONE; STEROID; RETINOIC ACID;

ADULT; AGED; ARTICLE; CHRONIC HAND ECZEMA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG WITHDRAWAL; FEMALE; HAND ECZEMA; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OPTIMISED EMOLLIENT THERAPY; PROBABILITY; PSORIASIS; PUVA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEVERE CHRONIC HAND ECZEMA; SKIN CARE; SWITZERLAND; TREATMENT RESPONSE; ADOLESCENT; CHRONIC DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; ECZEMA; HOSPITALIZATION; LONGITUDINAL STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECZEMA; HUMANS; LONGITUDINAL STUDIES; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SWITZERLAND; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 77955110472     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-10-4     Document Type: Article

References (47)

1. Halkier-Sorensen L. Occupational skin diseases. Contact dermatitis 1996, 35(1 Suppl):1-120.
2. Meding B. Epidemiology of hand eczema in an industrial city. Acta Derm Venereol Suppl (Stockh) 1990, 153:1-43.
3. Coenraads PJ, Bouma J, Diepgen TL. [Quality of life of patients with occupationally-induced hand eczema]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2004, 55(1):28-30.
4. Wallenhammar LM, Nyfjall M, Lindberg M, Meding B. Health-related quality of life and hand eczema--a comparison of two instruments, including factor analysis. J Invest Dermatol 2004, 122(6):1381-1389. 10.1111/j.0022-202X.2004.22604.x, 15175027.
5. Diepgen TL. [Chronic hand eczema: epidemiology and therapeutic evidence]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2008, 59(9):683-684. 686-689.
6. Meding B, Jarvholm B. Hand eczema in Swedish adults - changes in prevalence between 1983 and 1996. J Invest Dermatol 2002, 118(4):719-723. 10.1046/j.1523-1747.2002.01718.x, 11918722.
7. Diepgen TL, Agner T, Aberer W, Berth-Jones J, Cambazard F, Elsner P, McFadden J, Coenraads PJ. Management of chronic hand eczema. Contact dermatitis 2007, 57(4):203-210. 10.1111/j.1600-0536.2007.01179.x, 17868211.
8. Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis. The British journal of dermatology 2001, 144(3):523-532. 10.1046/j.1365-2133.2001.04078.x, 11260009.
9. Diepgen TL. Occupational skin-disease data in Europe. International archives of occupational and environmental health 2003, 76(5):331-338. 10.1007/s00420-002-0418-1, 12690490.
10. Diepgen TLSA. Werden Inzidenz und Prävalenz berufsbedingter Hauterkrankungen unterschätzt?. Arbeitsmed Sozialmed Umweltmed 2002, 37:477-480.
11. Molin S, Ruzicka T. [Alitretinoin: a new treatment option for chronic refractory hand eczema]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2008, 59(9):703-704. 706-709.
12. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, Hollo P, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. The British journal of dermatology 2008, 158(4):808-817. 10.1111/j.1365-2133.2008.08487.x, 18294310.
13. Ruzicka T, Larsen FG, Galewicz D, Horvath A, Coenraads PJ, Thestrup-Pedersen K, Ortonne JP, Zouboulis CC, Harsch M, Brown TC, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Archives of dermatology 2004, 140(12):1453-1459. 10.1001/archderm.140.12.1453, 15611422.
14. Bissonnette R, Worm M, Gerlach B, Guenther L, Cambazard F, Ruzicka T, Maares J, Brown TC. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. The British journal of dermatology 2009, 162(2):420-426. 10.1111/j.1365-2133.2009.09572.x, 19906075.
15. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. Jama 1996, 276(14):1172-1177. 10.1001/jama.276.14.1172, 8827972.
16. Adisesh A, Meyer JD, Cherry NM. Prognosis and work absence due to occupational contact dermatitis. Contact dermatitis 2002, 46(5):273-279. 10.1034/j.1600-0536.2002.460505.x, 12084080.
17. Cvetkovski RS, Rothman KJ, Olsen J, Mathiesen B, Iversen L, Johansen JD, Agner T. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. The British journal of dermatology 2005, 152(1):93-98. 10.1111/j.1365-2133.2005.06415.x, 15656807.
18. Ruzicka T LM, Lynde C, et al. Re-treatment study of alitretinoin (9-cis-retinoic acid) in severe chronic hand eczema refractory to topical treatment (Poster 280). EADV 2007,
19. Arzneimittel-Kompendium der Schweiz. Documed SA, Basel, Switzerland 2008,
20. Tarmed Schweiz. 04.01.2008 - 01.05.03.
21. Gut A. Recognized occupational diseases (1997-2006). Central Office for Statistics in Accident Insurance (SSUV).
22. Gut A. Costs incurred for recognized occupational diseases (1997-2006). Central Office for Statistics in Accident Insurance (SSUV).
23. NHS National Institute for Health and Clinical Excellence: Adalimumab for the treatment of adults with psoriasis (guidance developed using the single technology appraisal process). London, UK 2008, NHS.
24. NICE National Institute for Health and Clinical Excellence: full guidance on adalimumab for the treatment of psoriasis TA146. 2008, NICE.
25. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health technology assessment (Winchester, England) 2006, 10(46):1-233. i-iv.
26. Freemantle N AR, Stanley G. Quality of Life in chronic hand eczema as measured by the Dermatology Life Quality Index. ISPOR 2009,
27. NICE Alitretinoin for the treatment of severe chronic hand eczema (This guidance was developed using the single technology appraisal process). NICE technology appraisal guidance 2009, 177. NICE.
28. Swiss Federal Statistical Office. , http://www.bfs.admin.ch
29. Agner T, Held E. Skin protection programmes. Contact dermatitis 2002, 47(5):253-256. 10.1034/j.1600-0536.2002.470501.x, 12534528.
30. Weisshaar E, Radulescu M, Bock M, Albrecht U, Diepgen TL. Educational and dermatological aspects of secondary individual prevention in healthcare workers. Contact dermatitis 2006, 54(5):254-260. 10.1111/j.0105-1873.2006.00811.x, 16689809.
31. Marks R. The public health approach to the burden of common skin diseases in the community. The Journal of dermatology 2001, 28(11):602-605.
32. Raap U, Kenneweg C, Kapp A, Werfel T. [New and rarley used treatment options for refractory hand eczema: local UVA-1 phototherapy, retinoids, calcineurin inhibitors]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2008, 59(9):710. 712-714, 716.
33. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Archives of dermatology 2010, 146(1):46-54. 10.1001/archdermatol.2009.319, 20083692.
34. Accident Statistics 2003-2007 - Table 3.2.1: Occupational cases according to legal regulation. , http://www.unfallstatistik.ch/d/neuza/med_stat/med_stat_d.htm
35. Mathias CG, Morrison JH. Occupational skin diseases, United States. Results from the Bureau of Labor Statistics Annual Survey of Occupational Injuries and Illnesses, 1973 through 1984. Archives of dermatology 1988, 124(10):1519-1524. 10.1001/archderm.124.10.1519, 2971337.
36. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children?. The British journal of dermatology 2001, 144(3):514-522. 10.1046/j.1365-2133.2001.04077.x, 11260008.
37. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. The cost of atopic eczema. The British journal of dermatology 1996, 135(1):20-23. 10.1111/j.1365-2133.1996.tb03601.x, 8776353.
38. Hoyle M. Future drug prices and cost-effectiveness analyses. PharmacoEconomics 2008, 26(7):589-602. 10.2165/00019053-200826070-00006, 18563950.
39. National Institute for Health and Clinical Excellence - Guide to the methods of technology appraisal. , http://www.nice.org.uk/
40. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Medicine and health, Rhode Island 2001, 84(9):294-295.
41. Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F. The cost of atopic dermatitis in the Netherlands: an international comparison. The British journal of dermatology 2002, 147(4):716-724. 10.1046/j.1365-2133.2002.04964.x, 12366418.
42. Van Coevorden AM, Coenraads PJ, Svensson A, Bavinck JN, Diepgen TL, Naldi L, Elsner P, Williams HC. Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. The British journal of dermatology 2004, 151(2):446-451. 10.1111/j.1365-2133.2004.06040.x, 15327553.
43. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Expert opinion on pharmacotherapy 2002, 3(3):249-255. 10.1517/14656566.3.3.249, 11866675.
44. Viollier Laboratory Center. Basel, Switzerland 2008, Viollier.
45. Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008, 24(5):1473-1483. 10.1185/030079908X297826, 18413014.
46. Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, Erne P. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther 2006, 20(3):193-204. 10.1007/s10557-006-8282-y, 16775667.
47. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 2007, 18(9):1493-1499. 10.1093/annonc/mdm185, 17761705.